



(Please scan this QR code to view the RHP)

This is an abridged prospectus containing salient features of the red herring prospectus of CORONA Remedies Limited (the “Company”) dated December 2, 2025, (the “RHP” or “Red Herring Prospectus”) filed with the Registrar of Companies, Gujarat at Ahmedabad (the “RoC”). You are encouraged to read greater details available in the RHP, which is available at <https://www.sebi.gov.in/sebiweb/home/HomeAction.do?doListing=yes&sid=3&ssid=15&smid=11>. Unless otherwise specified all capitalised terms used herein and not specifically defined bear the same meaning as ascribed to them in the RHP. This abridged prospectus is not for distribution outside India.

**THIS ABRIDGED PROSPECTUS CONSISTS OF FOUR PAGES OF BID CUM APPLICATION FORM ALONG WITH INSTRUCTIONS AND EIGHT PAGES OF ABRIDGED PROSPECTUS. PLEASE ENSURE THAT YOU HAVE RECEIVED ALL THE PAGES.**

Please ensure that you have read the RHP (if in India), the preliminary international wrap dated December 2, 2025, (together with the RHP, the “Preliminary Offering Memorandum”) (if outside India), this abridged prospectus (“Abridged Prospectus”) and the general information document for investing in public offer (“GID”) undertaken through the Book Building Process before applying in the Offer (as defined below). The investors are advised to retain a copy of the RHP/Abridged Prospectus for their future reference.

You may obtain a physical copy of the Bid cum Application Form and the RHP from the Stock Exchanges (defined below), Members of the Syndicate, Registrar to the Offer, registrar and share transfer agents (“RTAs”), Collecting Depository Participants (“CDPs”), Registered Brokers, Bankers to the Offer, Self Certified Syndicate Banks (“SCSBs”) (each term as defined in the RHP). You may also download the RHP from the website of Securities and Exchange Board of India (“SEBI”) at [www.sebi.gov.in](http://www.sebi.gov.in), the websites of National Stock Exchange of India Limited (“NSE”) and BSE Limited (“BSE” and together with NSE, the “Stock Exchanges”) at [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com), respectively the website of the Company at [www.coronaremedies.com](http://www.coronaremedies.com) and the websites of the Book Running Lead Managers at [www.jmfl.com](http://www.jmfl.com), [www.iifcapital.com](http://www.iifcapital.com) and <https://investmentbank.kotak.com>, respectively.



**CORONA REMEDIES LIMITED**

Corporate Identity Number: U24231GJ2004PLC044656; Date of Incorporation: August 27, 2004

Registered and Corporate Office	Contact Person	Email and Telephone	Website
CORONA House, C – Mondeal Business Park, Near Gurudwara S. G. Highway, Thaltej Ahmedabad 380 059, Gujarat, India	<b>Chetna Prabhatkumar Dharajiya</b> <i>Company Secretary and Compliance Officer</i>	Email: <a href="mailto:complianceofficer@coronaremedies.com">complianceofficer@coronaremedies.com</a> Tel: +91 79 4023 3000	<a href="http://www.coronaremedies.com">www.coronaremedies.com</a>

**PROMOTERS OF OUR COMPANY: DR. KIRTIKUMAR LAXMIDAS MEHTA, NIRAVKUMAR KIRTIKUMAR MEHTA AND ANKUR KIRTIKUMAR MEHTA**

**DETAILS OF THE OFFER TO THE PUBLIC**

Type	Fresh Issue size	Offer for Sale size	Total Offer size	Eligibility and reservation	Share Reservation among			
					Qualified Institutional Buyers (“QIBs” / “QIB Bidders”)	Non-Institutional Bidders (“NIBs”)	Retail Individual Bidders (“RIBs”)	Employee Reservation Portion
Offer for Sale	Not Applicable	Up to [●] Equity Shares of face value of ₹ 10 each aggregating up to ₹ 6,553.71 million	Up to [●] Equity Shares of face value of ₹ 10 each aggregating up to ₹ 6,553.71 million	The Offer is being made pursuant to Regulation 6(1) of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (“SEBI ICDR Regulations”). For further details, see “Other Regulatory and Statutory Disclosures – Eligibility for the Offer” on page 390 of the RHP. For details in relation to share reservation among Qualified Institutional Buyers, Non-Institutional Investors, Retail Individual Investors and Eligible Employees, see “Offer Structure” on page 409 of the RHP.	Not more than 50% of the Net Offer shall be available to QIBs. 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds.	Not less than 15% of the Net Offer or the Net Offer less allocation to QIBs and RIBs	Not less than 35% of the Net Offer or Net Offer less allocation to QIBs and NIBs will be available for allocation	Up to [●] Equity Shares of face value of ₹ 10 each

The Equity Shares are proposed to be listed on the stock exchanges being National Stock Exchange of India Limited (“NSE”) and BSE Limited (“BSE”). For the purpose of the Offer, NSE is the Designated Stock Exchange (the “Designated Stock Exchange”).

**DETAILS OF THE SELLING SHAREHOLDERS, OFFER FOR SALE AND WEIGHTED AVERAGE COST OF ACQUISITION**

Name of the Selling Shareholder	Type of Selling Shareholder	Maximum number of Offered Shares / Amount (₹ in million)	Weighted average cost of acquisition per Equity Share (in ₹)*
Dr. Kirtikumar Laxmidas Mehta	Promoter Selling Shareholder	Up to [●] Equity Shares of face value of ₹10 each aggregating up to ₹1,298.41 million	0.10
Minaxi Kirtikumar Mehta	Promoter Group Selling Shareholder	Up to [●] Equity Shares of face value of ₹10 each aggregating up to ₹766.07 million	0.08
Dipabahan Niravkumar Mehta	Promoter Group Selling Shareholder	Up to [●] Equity Shares of face value of ₹10 each aggregating up to ₹103.87 million	1.91
Brinda Ankur Mehta	Promoter Group Selling Shareholder	Up to [●] Equity Shares of face value of ₹10 each aggregating up to ₹103.87 million	0.09
Sepia Investments Limited	Investor Selling Shareholder	Up to [●] Equity Shares of face value of ₹10 each aggregating up to ₹ 4,046.00 million	408.76
Anchor Partners	Investor Selling Shareholder	Up to [●] Equity Shares of face value of ₹10 each aggregating up to ₹151.25 million	408.76
Sage Investment Trust	Investor Selling Shareholder	Up to [●] Equity Shares of face value of ₹10 each aggregating up to ₹84.24 million	408.76

\*As certified by O.R. Maloo & Co., Chartered Accountants, with firm registration number 0135561W, by way of their certificate dated December 2, 2025.

**IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS**

**PRICE BAND, MINIMUM BID LOT & INDICATIVE TIMELINES**

Price Band	₹ 1,008 per Equity Share of face value of ₹ 10 each (Floor Price) to ₹ 1,062 per Equity Share of face value of ₹ 10 each (Cap Price).
Minimum Bid Lot Size	A Minimum of 14 Equity Shares and in multiples of 14 Equity Shares thereafter
Anchor Investor Bidding Date	Friday, December 5, 2025
Bid/Offer Opens On	Monday, December 8, 2025
Bid/Offer Closes On <sup>(1)</sup>	Wednesday, December 10, 2025
Finalisation of Basis of Allotment with the Designated Stock Exchange	On or about December 11, 2025
Initiation of refunds (if any, for Anchor Investors) / unblocking of funds from ASBA Account	On or about December 12, 2025
Credit of Equity Shares to Demat accounts of Allottees	On or about December 12, 2025
Commencement of trading of the Equity Shares on the Stock Exchanges	On or about December 15, 2025

<sup>(1)</sup> UPI mandate end time and date shall be at 5:00 pm on the Bid/Offer Closing Date.

For details of the Price Band and the basis for the Offer Price, please refer to the price band advertisement and the section titled “Basis for Offer Price” on page 126 of the RHP.

**WEIGHTED AVERAGE COST OF ACQUISITION OF ALL EQUITY SHARES TRANSACTED IN LAST ONE YEAR, 18 MONTHS AND THREE YEARS PRECEDING THE DATE OF THE RED HERRING PROSPECTUS**

Period	Weighted average cost of acquisition (in ₹) <sup>(1)</sup>	Cap Price is ‘x’ times the weighted average cost of acquisition	Range of acquisition price: lowest price – highest price (in ₹) <sup>(1)</sup>
Last one year preceding the date of this Red Herring Prospectus	-	-	-
Last 18 months preceding the date of this Red Herring Prospectus	0.09	11,800.00	Nil – 0.14
Last three years preceding the date of this Red Herring Prospectus	0.09	11,800.00	Nil – 0.14

<sup>(1)</sup> As certified by O.R. Maloo & Co., Chartered Accountants, with firm registration number 0135561W, by way of their certificate dated December 2, 2025.

The Equity Shares have not been and will not be registered under the U.S. Securities Act or any state securities laws in the United States and, unless so registered, may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”) and applicable state securities laws. Accordingly, the Equity Shares are only being offered and sold outside the United States in “offshore transactions”, as defined in, and in reliance on, Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales occur. The Equity Shares have not been and will not be registered, listed or otherwise qualified in any other jurisdiction outside India and may not be offered or sold, and Bids may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction.

**RISKS IN RELATION TO THE FIRST OFFER**

This being the first public offer of our Company, there has been no formal market for the Equity Shares. The face value of the Equity Shares is ₹10. The Offer Price/ Floor Price/ Cap Price, as determined and justified by our Company, in consultation with the BRLMs in accordance with the SEBI ICDR Regulations and as stated in “Basis for Offer Price”, beginning on page 126, should not be taken to be indicative of the market price of the Equity Shares after such Equity Shares are listed. No assurance can be given regarding an active and/ or sustained trading in the Equity Shares nor regarding the price at which the Equity Shares will be traded after listing.

**GENERAL RISKS**

Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in the Offer unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Offer. For taking an investment decision, investors must rely on their own examination of our Company and the Offer, including the risks involved. The Equity Shares have not been recommended or approved by the SEBI, nor does SEBI guarantee the accuracy or adequacy of the contents of the Red Herring Prospectus. Specific attention of the investors is invited to “Risk Factors” on page beginning on page 30 of the RHP.

**PROCEDURE**

You may obtain a physical copy of the Bid cum Application Form and the RHP from the Stock Exchanges, Members of the Syndicate, Registrar to the Offer, RTAs, CDPs, Registered Brokers, Bankers to the Offer, Investors’ Associations or SCSBs.

If you wish to know about processes and procedures applicable to the Offer, you may request for a copy of the RHP and/or the GID from the BRLMs or download it from the website of SEBI at [www.sebi.gov.in](http://www.sebi.gov.in), the websites of NSE and BSE at [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com), respectively, and the websites of the BRLMs at i.e., at [www.jmfml.com](http://www.jmfml.com), [www.iiflcapital.com](http://www.iiflcapital.com) and <https://investmentbank.kotak.com>, respectively..

**PAST PRICE INFORMATION OF BRLMS**

Sr. No.	Issue name	BRLM Name	+/- % change in closing price, [+/- % change in closing benchmark] - 30 <sup>th</sup> calendar days from listing	+/- % change in closing price, [+/- % change in closing benchmark] - 90 <sup>th</sup> calendar days from listing	+/- % change in closing price, [+/- % change in closing benchmark] - 180 <sup>th</sup> calendar days from listing
1.	Capillary Technologies India Limited	JM, IIFL	Not Applicable	Not Applicable	Not Applicable
2.	Tenneco Clean Air India Limited	JM	Not Applicable	Not Applicable	Not Applicable
3.	Emmvee Photovoltaic Power Limited	JM, IIFL, Kotak	Not Applicable	Not Applicable	Not Applicable
4.	Studds Accessories Limited	IIFL	Not Applicable	Not Applicable	Not Applicable
5.	Canara HSBC Life Insurance Company Limited	JM	13.50% [0.78%]	Not Applicable	Not Applicable
6.	Rubicon Research Limited	JM, IIFL	+47.18%, [+1.27%]	Not Applicable	Not Applicable
7.	Tata Capital Limited	IIFL, Kotak	-0.11%, [+1.85%]	Not Applicable	Not Applicable
8.	Seshaasai Technologies Limited	IIFL	-11.45%, [+5.89%]	Not Applicable	Not Applicable
9.	Sudeep Pharma Limited	IIFL	Not Applicable	Not Applicable	Not Applicable
10.	Canara Robeco Asset Management Limited	JM	9.81% [1.27%]	Not Applicable	Not Applicable
11.	Wework India Management Limited	JM, Kotak	-2.48% [0.82%]	Not Applicable	Not Applicable
12.	Urban Company Limited	JM, Kotak	53.83% [1.01%]	Not Applicable	Not Applicable
13.	Vikram Solar Limited	JM	-1.48% [1.40%]	-13.25% [5.49%]	Not Applicable
14.	JSW Cement Limited	JM, Kotak	1.17% [1.96%]	-16.64% [4.32%]	Not Applicable

**IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS**

15.	Physicwallah Limited	Kotak	Not applicable	Not applicable	Not applicable
16.	Billionbrains Garage Ventures Limited	Kotak	Not applicable	Not applicable	Not applicable
17.	Lenskart Solutions Limited	Kotak	Not applicable	Not applicable	Not applicable
18.	Orkla India Limited	Kotak	Not applicable	Not applicable	Not applicable
19.	Bluestone Jewellery and Lifestyle Limited	Kotak, IIFL	+15.13%, [+1.40%]	+11.17%, [+3.72%]	Not applicable

Source: [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com)

For further details, please refer to Other Regulatory and Statutory Disclosures - Price information of past issues handled by the Book Running Lead Managers on page 396 of the RHP

**BOOK RUNNING LEAD MANAGERS**

<b>JM Financial Limited</b> Tel: +91 22663 03030 E-mail: <a href="mailto:corona.ipo@jmf.com">corona.ipo@jmf.com</a> Investor Grievance E-mail: <a href="mailto:grievance.ibd@jmf.com">grievance.ibd@jmf.com</a>	<b>IIFL Capital Services Limited</b> (formerly known as IIFL Securities Limited) Tel: +91 22464 64728; E-mail: <a href="mailto:corona.ipo@iiflcap.com">corona.ipo@iiflcap.com</a> Investor Grievance E-mail: <a href="mailto:ig.ib@iiflcap.com">ig.ib@iiflcap.com</a>	<b>Kotak Mahindra Capital Company Limited</b> Tel: +91 22433 60000 E-mail: <a href="mailto:coronaremedies.ipo@kotak.com">coronaremedies.ipo@kotak.com</a> Investor Grievance E-mail: <a href="mailto:kmccredressal@kotak.com">kmccredressal@kotak.com</a>
--	--	--

<b>Name of Syndicate Members</b>	Kotak Securities Limited and JM Financial Services Limited
<b>Name of Registrar to the Offer</b>	<b>Bigshare Services Private Limited</b> Tel: +91 22626 38200; E-mail: <a href="mailto:ipo@bigshareonline.com">ipo@bigshareonline.com</a> ; Investor Grievance E-mail: <a href="mailto:investor@bigshareonline.com">investor@bigshareonline.com</a>
<b>Name of Statutory Auditors</b>	Deloitte Haskins & Sells LLP, Chartered Accountants
<b>Name of Credit Rating Agency and the rating or grading obtained, if any</b>	As this is an Offer of Equity Shares, credit rating is not required
<b>Name of Debenture Trustee</b>	Not applicable
<b>Self Certified Syndicate Bank(s) and mobile applications enabled for UPI Mechanism</b>	In accordance with SEBI ICDR Master Circular and SEBI Circular No. SEBI/HO/CFD/DIL2/CIR/P/2019/85 dated July 26, 2019, UPI Bidders Bidding using the UPI Mechanism may only apply through the SCSBs and mobile applications whose names appears on the website of the SEBI, i.e., ( <a href="http://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&amp;intmlId=40">www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&amp;intmlId=40</a> ) for SCSBs and ( <a href="http://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&amp;intmlId=43">www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&amp;intmlId=43</a> ) for mobile applications, respectively, as updated from time to time. A list of SCSBs and mobile applications, which are live for applying in public issues using UPI Mechanism is available on ( <a href="https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&amp;intmlId=40">https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&amp;intmlId=40</a> ) and ( <a href="https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&amp;intmlId=43">https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&amp;intmlId=43</a> ).
<b>Self-Certified Syndicate Bank(s) or SCSB(s)</b>	The banks registered with SEBI, which offer the facility of ASBA services, (i) in relation to ASBA, where the Bid Amount will be blocked by authorising an SCSB, a list of which is available on the website of SEBI at <a href="http://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&amp;intmlId=34">www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&amp;intmlId=34</a> and updated from time to time and at such other websites as may be prescribed by SEBI from time to time, (ii) in relation to UPI Bidders using the UPI Mechanism, a list of which is available on the website of SEBI at <a href="http://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&amp;intmlId=40">www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&amp;intmlId=40</a> and updated from time to time and at such other websites as may be prescribed by SEBI from time to time, and (ii) The banks registered with SEBI, enabled for UPI Mechanism, a list of which is available on the website of SEBI at <a href="http://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&amp;intmlId=40">www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&amp;intmlId=40</a> or such other website as updated from time to time.
<b>Syndicate SCSB Branches</b>	In relation to Bids (other than Bids by Anchor Investors and RIIs) submitted under the ASBA process to a member of the Syndicate, the list of branches of the SCSBs at the Specified Locations named by the respective SCSBs to receive deposits of Bid cum Application Forms from the members of the Syndicate is available on the website of the SEBI at <a href="http://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognised=yes&amp;intmlId=35">http://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognised=yes&amp;intmlId=35</a> , which may be updated from time to time or any such other website as may be prescribed by SEBI from time to time.
<b>Registered Brokers</b>	Bidders can submit ASBA Forms in the Offer using the stockbroker network of the Stock Exchanges, i.e., through the Registered Brokers at the Broker Centres. The list of the Registered Brokers eligible to accept ASBA Forms, including details such as postal address, telephone number and e-mail address, is provided on the websites of the Stock Exchanges at <a href="http://www.bseindia.com">www.bseindia.com</a> and <a href="http://www.nseindia.com">www.nseindia.com</a> , respectively, as updated from time to time.
<b>Details regarding website address(es)/ link(s) from which the investor can obtain a list of RTAs, CDPs and stock brokers who can accept applications from investors, as applicable</b>	The list of the RTAs eligible to accept ASBA Forms at the Designated RTA Locations, including details such as address, telephone number and e-mail address, is provided on the websites of the BSE and NSE at <a href="http://www.bseindia.com/Static/Markets/PublicIssues/RtaDp.aspx?">www.bseindia.com/Static/Markets/PublicIssues/RtaDp.aspx?</a> and <a href="http://www.nseindia.com/products/content/equities/ipos/asba_procedures.htm">www.nseindia.com/products/content/equities/ipos/asba_procedures.htm</a> , respectively, as updated from time to time. The list of the CDPs eligible to accept ASBA Forms at the Designated CDP Locations, including details such as their name and contact details, is provided on the websites of the Stock Exchanges at <a href="http://www.bseindia.com/Static/Markets/PublicIssues/RtaDp.aspx?">www.bseindia.com/Static/Markets/PublicIssues/RtaDp.aspx?</a> and <a href="http://www.nseindia.com/products/content/equities/ipos/asba_procedures.htm">www.nseindia.com/products/content/equities/ipos/asba_procedures.htm</a> , respectively, as updated from time to time. For further details, see "Offer Procedure" on page 415 of the RHP.

**THE PROMOTERS OF OUR COMPANY**

Sr. No.	Name	Individual/ Corporate	Experience and Educational Qualification
1	Dr. Kirtikumar Laxmidas Mehta	Individual	He has been associated with our Company since incorporation. He holds a bachelor's degree in medicine and surgery from Gujarat University, Ahmedabad, Gujarat. He has over 36 years of experience in the medical and pharmaceutical industry.
2	Niravkumar Kirtikumar Mehta	Individual	He has been associated with our Company since May 30, 2007. He holds a diploma in pharmacy from Saurashtra University, Rajkot, Gujarat and a bachelor's degree in pharmacy from University of Pune, Pune, Maharashtra. He has 20 years of experience in the strategic management, pharmaceutical research and marketing. He has received 2024 Hurun Industry Achievement Award - Pharmaceuticals in 2025 presented by Hurun India.
3	Ankur Kirtikumar Mehta	Individual	He has been associated with our Company since incorporation. He holds a bachelor's degree in science from Saurashtra University, Rajkot, Gujarat and a master's degree in business administration from Gujarat University, Ahmedabad, Gujarat. He has 20 years of experience in the pharmaceutical industry.

For details in respect of the Promoter, please see the section entitled titled "Our Promoter and Promoter Group" beginning on page 278 of the RHP.

**OUR BUSINESS OVERVIEW AND STRATEGY**

**Company Overview:** We are an India-focused branded pharmaceutical formulation company engaged in developing, manufacturing and marketing products in women's healthcare, cardio-diabeto, pain management, urology and other therapeutic areas. According to the CRISIL Intelligence Report. We are the fastest growing company among the top 30 companies in the Indian Pharmaceutical Market ("IPM") in terms of domestic sales in the IPM, between MAT June 2024 and MAT June 2025. During this period, our domestic sales grew at a CAGR of 13.58% compared to the IPM which grew at a CAGR of 7.90% (Source: CRISIL Intelligence Report).

**Product/Service Offering:** Our diversified product portfolio comprises 71 brands catering to a range of therapeutic areas such as women's healthcare, cardio-diabeto, pain management and urology and others/multispecialty pharmaceuticals (comprising vitamins/minerals/nutrition ("VMN"), gastrointestinal and respiratory), as of June 30, 2025. Of our targeted therapeutic areas, our women's healthcare segment contributed to 28.56% (or ₹4,080.26 million), cardio-diabeto (comprising cardio-vascular and anti-diabetic areas) contributed 23.38% (or ₹3,339.96 million), pain management contributed 11.79% (or ₹1,684.38 million) and urology contributed 4.53% (or ₹646.65 million) to our domestic sales for MAT June 2025.

**Domestic sales attributable to each of our therapeutic areas**

Therapeutic Area	For MAT							
	June 2025		June 2024		June 2023		June 2022	
	Amount (₹ in millions)	% of domestic sales	Amount (₹ in millions)	% of domestic sales	Amount (₹ in millions)	% of domestic sales	Amount (₹ in millions)	% of domestic sales
Women's healthcare	4,080.26	28.56%	3,489.78	27.75%	3,114.22	28.26%	2,322.11	25.88%
Cardio-diabeto	3,339.96	23.38%	2,963.95	23.57%	2,366.69	21.48%	1,841.75	20.53%
Pain Management	1,684.38	11.79%	1,345.06	10.69%	1,069.27	9.70%	994.43	11.08%
Urology	646.65	4.53%	267.26	2.13%	194.30	1.76%	159.17	1.77%
Others	4,533.64	31.74%	4,510.68	35.87%	4,276.13	38.80%	3,654.05	40.73%
<b>Total</b>	<b>14,284.89</b>	<b>100.00%</b>	<b>12,576.74</b>	<b>100.00%</b>	<b>11,020.62</b>	<b>100.00%</b>	<b>8,971.51</b>	<b>100.00%</b>

Notes: The Company's addressable market includes sales for selected subgroups mentioned in the CRISIL Intelligence Report.

1. The women's healthcare market includes subgroups from gynaecological, cardiac, blood related, anti-diabetic vitamins / minerals / nutrients, gastro intestinal, anti-neoplastics, anti-infectives, pain / analgesics and derma. 2. The cardio-diabeto market includes subgroups from anti diabetic, cardiac, blood related, pain / analgesics and hormones. 3. The pain-management market includes subgroups from neuro / CNS and pain / analgesics. 4. The urology market includes subgroups from urology, sex stimulants / rejuvenators and hormones. 5. The others market consists of sales from all the subgroups excluding subgroups mentioned in the above categories.

Source: CRISIL Intelligence Report; see "Industry Overview - Review of competition in the IPM - Trend in therapy wise domestic sales in CORONA's addressable market in the IPM" on page 188.

**Geographies Served:** Our presence spans over 20 countries, including India, the United Arab Emirates, Uzbekistan, Philippines, Kenya, Cyprus and others, where we employ a calibrated and market-specific approach that takes into account regulatory landscapes, market size, competitive environments, and product demand in each region.

**Revenue segmentation by geographies:**

Set out below is a breakdown of our revenue from operations by geography for the periods and financial years indicated:

Particulars	Three months ended June 30, 2025		Financial Year					
			2025		2024		2023	
	Amount (in ₹ million)	% of revenue from operations	Amount (in ₹ million)	% of revenue from operations	Amount (in ₹ million)	% of revenue from operations	Amount (in ₹ million)	% of revenue from operations
Revenue from operations – within India	3,338.54	96.34%	11,524.56	96.33%	9,802.28	96.62%	8,521.61	96.39%
Revenue from operations – outside India	126.88	3.66%	439.59	3.67%	342.46	3.38%	318.89	3.61%
<b>Total revenue from operations</b>	<b>3,465.42</b>	<b>100.00%</b>	<b>11,964.15</b>	<b>100.00%</b>	<b>10,144.74</b>	<b>100.00%</b>	<b>8,840.50</b>	<b>100.00%</b>

**Key Performance Indicators:**

Our Company confirms that it shall continue to disclose all the KPIs included in this section on a periodic basis, at least once in a year (or any lesser period as determined by the Board of Directors of our Company) until one year after the date of listing of the Equity Shares on the Stock Exchanges or for such other duration as may be required under the SEBI ICDR Regulations.

(₹ in million, unless mentioned otherwise)

Particulars	Unit	As of and for the three months ended June 30, 2025	As of and for the Financial Year		
			2025	2024	2023
Revenue from operations	₹ in million	3,465.42	11,964.15	10,144.74	8,840.50
Growth of revenue from operations	%	NA	17.93%	14.75%	NA
Revenue from operations – domestic (as a percentage of total revenue from operations)	%	96.34%	96.33%	96.62%	96.39%
Revenue from operations – international (as a percentage of total revenue from operations)	%	3.66%	3.67%	3.38%	3.61%
Revenue from operations – owned manufacturing (as a percentage of total revenue from operations)	%	62.75%	64.01%	64.52%	62.02%
Gross Profit	₹ in million	2,807.62	9,599.04	7,876.46	6,730.96
Growth of Gross Profit	%	NA	21.87%	17.02%	NA
Gross Profit Margin	%	81.02%	80.23%	77.64%	76.14%
EBITDA	₹ in million	717.96	2,459.13	1,611.90	1,350.30
Growth of EBITDA	%	NA	52.56%	19.37%	NA
EBITDA Margin	%	20.72%	20.55%	15.89%	15.27%
Profit after tax	₹ in million	461.96	1,494.34	905.03	849.29
Growth of PAT	%	NA	65.11%	6.56%	NA
PAT Margin (%)	%	13.33%	12.49%	8.92%	9.61%
Return on Capital Employed (RoCE)	%	11.28% <sup>†</sup>	41.32%	31.19%	28.36%
Adjusted Return on Capital Employed (Adj. RoCE)	%	14.53% <sup>†</sup>	47.87%	37.53%	36.62%
Return on Equity (RoE)	%	7.61% <sup>†</sup>	27.50%	20.36%	23.29%
OCF / EBITDA	%	35.33% <sup>‡</sup>	77.46%	97.25%	76.06%
Net Working Capital Days	Days	68.62 <sup>**</sup>	24.17	23.43	31.20
Net Debt / (Net Cash)	₹ in million	(179.99)	(66.40)	621.20	(952.47)

For further details, please refer to "Basis for Offer Price - Key Performance Indicators" on page 129 of the RHP.

**Client Profile or Industries Served:** We have a diverse customer base, comprising pharmacies, specialty treatment facilities, other outpatient clients, physicians and hospitals.

**Intellectual Property:** We rely on a range of trademarks and other proprietary rights, such as trade secrets, know-how and confidentiality agreements to develop, maintain and strengthen our competitive position. In addition, we seek copyright protection of our packaging and labels. We have registered 194 trademarks with 29 applications for trademarks currently pending approval, and 67 of our trademarks have been opposed or objected to. Also see "Risk Factors - As of June 30, 2025, with a portfolio of 71 brands, we held 194 registered trademarks, with 29 pending trademark applications and 67 opposed/ objected/ refused / abandoned trademarks under certain classes of trademarks. If we are unable to obtain trademarks for our products and brands or protect other proprietary information, our business, results of operations, financial condition and cash flows may be adversely affected" on page 36 of the RHP.

**IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS**

**Market Share:** We are the 17<sup>th</sup> largest by market share in our Covered Market based on domestic sales for MAT June 2025, and were the third fastest growing Indian pharmaceutical company in terms of prescriptions in targeted specialties (among consultant physicians, cardiologists, diabetologists, gynaecologists, orthopaedics and urologists) between MAT June 2022 and 2025. We are ranked 7<sup>th</sup> among top 30 players in IPM in terms of increase in market share from MAT June 2022 to MAT June 2025 (Source: *CRISIL Intelligence Report*).

**Manufacturing Plant:** We operate two manufacturing facilities, located in the states of Gujarat and Himachal Pradesh and are in the process of commissioning a hormone manufacturing facility in the state of Gujarat.

**Employee Strength:** As of June 30, 2025, we had 4,573 permanent employees.

**BOARD OF DIRECTORS**

Sr. No.	Name	Designation	Experience & Educational Qualification	Directorships in other companies
1.	<b>Dr. Kirtikumar Laxmidas Mehta</b>	Chairman and Non-Executive Director	He holds a bachelor's degree in medicine and surgery from Gujarat University, Ahmedabad, Gujarat. He has over 36 years of experience in the medical and pharmaceutical industry.	<i>Indian Companies:</i> Nil <i>Foreign Companies:</i> Nil
2.	<b>Niravkumar Kirtikumar Mehta</b>	Managing Director and Chief Executive Officer	He holds a diploma in pharmacy from Saurashtra University, Rajkot, Gujarat and a bachelor's degree in pharmacy from University of Pune, Pune, Maharashtra. He has 20 years of experience in the strategic management, pharmaceutical research and marketing. He has received 2024 Hurun Industry Achievement Award - Pharmaceuticals in 2025 presented by Hurun India.	<i>Indian Companies:</i> Nil <i>Foreign Companies:</i> Nil
3.	<b>Ankur Kirtikumar Mehta</b>	Joint Managing Director	He holds a bachelor's degree in science from Saurashtra University, Rajkot, Gujarat and a master's degree in business administration from Gujarat University, Ahmedabad, Gujarat. He has 20 years of experience in the pharmaceutical industry.	<i>Indian Companies:</i> Nil <i>Foreign Companies:</i> Nil
4.	<b>Viral Bhupendrabhai Sitwala</b>	Whole-Time Director	He holds a diploma in pharmacy from Saurashtra University, Rajkot, Gujarat. He is responsible for overall operation and quality function for all the manufacturing plants of the Company. He has 20 years of experience in the pharmaceutical industry. He was previously associated with FDC Limited and American Remedies Limited.	<i>Indian Companies:</i> Nil <i>Foreign Companies:</i> Nil
5.	<b>Ameetkumar Hiranyakumar Desai</b>	Independent Director	He holds a bachelor's degree in business administration from Sardar Patel University, Anand, Gujarat. He also holds a master's degree in business administration with specialisation in finance from Gujarat University, Ahmedabad, Gujarat. He has completed the leading and managing people program certified from and by The Wharton School, University of Pennsylvania, Philadelphia, Pennsylvania, United States. He currently serves on the board of directors of Adani Aerospace and Defence Limited, Ambuja Cements Limited, Adani Defence Systems and Technologies Limited, Adani Naval Defence Systems and Technologies Limited, and JM Financial Asset Reconstruction company Limited. He has over 19 years of experience across pharmaceutical, defence and finance industries.	<i>Indian Companies:</i> 1. Adani Aerospace and Defence Limited; 2. Adani Defence Systems and Technologies Limited; 3. Adani Naval Defence Systems and Technologies Limited; 4. Ambuja Cements Limited; 5. Ganesh Housing Corporation Limited; 6. Hester Biosciences Limited; 7. JM Financial Asset Reconstruction Company Limited; 8. Nxgn Sports Interactive Private Limited; and 9. Sourcepro Infotech Private Limited. <i>Foreign Companies:</i> Nil
6.	<b>Monica Hemal Kanuga</b>	Independent Director	She holds a bachelor's degree in commerce from Gujarat University, Ahmedabad, Gujarat. She also holds a bachelor's degree in law (general) and a bachelor's degree in law (special) from Gujarat University, Ahmedabad, Gujarat. She is registered as, an insolvency professional with Insolvency and Bankruptcy Board of India and Insolvency Professionals Agency, and a company secretary from the Institute of Company Secretaries of India. She has over 30 years of experience in corporate compliance and governance.	<i>Indian Companies:</i> Nil <i>Foreign Companies:</i> Nil
7.	<b>Shirish Gundopant Belapure</b>	Independent Director	He holds a bachelor's degree in pharmacy from Shivaji University, Kolhapur, Maharashtra. He also holds a master's degree in pharmacy (pharmacognosy) from Nagpur University, Nagpur, Maharashtra. He has also completed a long-term diploma course in business management from the Nagpur Management Association, Nagpur, Maharashtra. He was previously associated with Zydus Hospira Oncology Private Limited as the managing director, Zydus Lifesciences Limited as the president – manufacturing (formulations), and was also associated with Cipla Limited, Sun Pharmaceuticals Industries Limited, M. J. Pharmaceuticals Limited, The Fairdeal Corporation (Private) Limited, Griffon Laboratoires Private Limited and Cyanamid India Limited. He has over 17 years of experience in the pharmaceutical industry.	<i>Indian Companies:</i> 1. Innova Captab Limited; 2. Jubilant Pharmova Limited; 3. Jubilant Generics Limited; 4. Natural Capsules Limited; and 5. Uniza Lifecare Private Limited. <i>Foreign Companies:</i> Nil

Sr. No.	Name	Designation	Experience & Educational Qualification	Directorships in other companies
8.	<b>Bhaskar Vemban Iyer</b>	Independent Director	He holds a bachelor's degree in science and a master's degree in marketing management, both from University of Bombay, Mumbai, Maharashtra. He was previously associated with Abbott Healthcare Private Limited, Advent Pharma Limited and Quadria Capital. He has over 14 years of experience across in the pharmaceutical and healthcare industry.	<i>Indian Companies:</i> 1. RPG Lifesciences Limited; and 2. Themis Medicare Limited. <i>Foreign Companies:</i> Nil

For further details in relation to our Board of Directors, see “*Our Management*” beginning on page 260 of the RHP.

#### OBJECTS OF THE OFFER

The objects of the Offer are to achieve the benefits of listing the Equity Shares on the Stock Exchanges and for the Offer for Sale of up to [●] Equity Shares of face value of ₹10 each aggregating up to ₹6,553.71 million. Each Selling Shareholder has, severally and not jointly, authorised its participation in the Offer for Sale to the extent of its respective portion of the Offered Shares, pursuant to its respective consent letter. Set forth hereunder are the details of the number of Equity Shares offered by each of the Selling Shareholders in the Offer:

Name of the Selling Shareholder	Maximum number of Offered Shares/ Amount (in ₹ million)
Dr. Kirtikumar Laxmidas Mehta	Up to [●] Equity Shares of face value of ₹10 each aggregating up to ₹1,298.41 million
Minaxi Kirtikumar Mehta	Up to [●] Equity Shares of face value of ₹10 each aggregating up to ₹766.07 million
Dipabehen Niravkumar Mehta	Up to [●] Equity Shares of face value of ₹10 each aggregating up to ₹103.87 million
Brinda Ankur Mehta	Up to [●] Equity Shares of face value of ₹10 each aggregating up to ₹103.87 million
Sepia Investments Limited	Up to [●] Equity Shares of face value of ₹10 each aggregating up to ₹4,046.00 million
Anchor Partners	Up to [●] Equity Shares of face value of ₹10 each aggregating up to ₹151.25 million
Sage Investment Trust	Up to [●] Equity Shares of face value of ₹10 each aggregating up to ₹84.24 million

For further details, see “*The Offer*” on page 86 of the RHP.

Our Company expects that listing of the Equity Shares will enhance our visibility and brand and provide liquidity to its existing Shareholders. Listing will also provide a public market for the Equity Shares in India.

#### Utilization of the Offer Proceeds

Our Company will not receive any proceeds from the Offer (“*Offer Proceeds*”) and the Offer Proceeds will be received by the Selling Shareholders, in proportion to the Offered Shares sold by the respective Selling Shareholders as part of the Offer after deducting their portion of the Offer related expenses and the relevant taxes thereon. See “*The Offer*” and “*Other Regulatory and Statutory Disclosures*” on pages 86 and 389, respectively.

**Details and reasons for non-deployment or delay in deployment of proceeds or changes in utilisation of issue proceeds of past public offers / rights issues, if any, of our Company in the preceding 10 years:** Not applicable.

**Terms of Issuance of Convertible Security, if any:** Not applicable.

**Name of Monitoring Agency:** Not applicable.

**Shareholding Pattern as on the date of the RHP:**

Category of shareholder	Pre-Offer number of fully paid-up Equity Shares of face value of ₹10 each	% Holding of pre-Offer Equity Share capital
Promoters and Promoter Group	44,338,558	72.50%
Public	16,821,530	27.50%
<b>Total</b>	<b>61,160,088</b>	<b>100.00%</b>

**Number/ amount of Equity Shares proposed to be sold by the Selling Shareholders:** Up to [●] Equity Shares of face value of ₹10 each aggregating up to ₹6553.71 million.

#### SUMMARY OF THE RESTATED FINANCIAL INFORMATION

The summary of selected financial information of our Company derived from the Restated Consolidated Financial Information is set forth below:

(₹ in million, unless otherwise specified)

Particulars	As at and for the three months ended June 30, 2025	As at and for the year ended March 31, 2025	As at and for the year ended March 31, 2024	As at and for the year ended March 31, 2023
Equity share capital	611.60	611.60	611.60	611.60
Net Worth	6,070.24	6,063.44	4,804.07	4,085.20
Revenue from operations	3,465.42	11,964.15	10,144.74	8,840.50
Profit after tax	461.96	1,494.34	905.03	849.29
Earnings per share (in ₹)	7.55*	24.43	14.80	14.57
Net Asset Value per Equity Share (in ₹)	99.25	99.14	78.55	70.06
Total borrowings	1,066.48	626.95	1,341.42	23.31

For further details, see “*Restated Consolidated Financial Information*” and “*Other Financial Information*” beginning on pages 283 and 339, respectively, of the RHP.

#### INTERNAL RISK FACTORS

Below mentioned risks are the top 5 risk factors as per the RHP. For further details, see “*Risk Factors*” on page 30 of the RHP.

- The therapeutic areas of women's healthcare, cardio-diabeto and pain management contributed to an aggregate of ₹2,257.26 million (or 65.14%) and ₹7,465.54 million (or 62.40%) of our revenue from operations for the three months ended June 30, 2025 and the Financial Year 2025, respectively. If our products in these or other therapeutic areas which contribute significantly to our revenue from operations do not perform as expected or if competing products become available and gain wider market acceptance, our business, results of operations, financial condition and cash flows may be adversely affected.

**IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS**

2. Our 27 “engine” brands (and in particular, our B-29 and Myoril brands) accounted for 72.34% of our domestic sales during the MAT June 2025 period, and any adverse developments affecting the sales of our “engine” brands could have an adverse effect on our business, results of operations, financial condition and cash flows.
3. We derive a significant majority of our revenue from our operations within India (constituting 96.34% and 96.33% of our revenue from operations during the three months ended June 30, 2025 and the Financial Year 2025, respectively). In the event of a fall in demand for our products in India, or if we fail to successfully expand into international markets, our business, results of operations, financial conditions and cash flows may be adversely affected.
4. A significant portion of our domestic sales are concentrated in the states of Gujarat, Maharashtra, Chhattisgarh, Goa and Madhya Pradesh (accounting for 47.30% of our domestic sales for MAT June 2025). Any adverse developments affecting our sales in these regions could have an adverse effect on our business, results of operations, financial condition and cash flows.
5. 70.10% of our domestic sales for MAT June 2025 were derived from chronic and sub-chronic therapeutic segments, which are subject to risks and uncertainties that could adversely affect our business, results of operations, financial condition and cash flows.

**SUMMARY OF OUTSTANDING LITIGATIONS, CLAIMS AND REGULATORY ACTION**

- A. A summary of outstanding litigation proceedings involving our Company, our Directors, our Promoters, our Key Managerial Personnel, our Senior Management and our Group Company, as disclosed in this Red Herring Prospectus, is provided below:

Category of individuals/ entities	Criminal proceedings	Tax proceedings	Statutory or regulatory actions	Disciplinary actions by the SEBI or Stock Exchanges against our Promoters in the last five years, including outstanding action	Material civil litigations as per the Materiality Policy	Aggregate amount involved* (in ₹ million)
<b>Company</b>						
By our Company	4	Nil	N.A	N.A	1	0.44
Against our Company	Nil	Nil	6 <sup>#</sup>	N.A	Nil	Nil
<b>Directors</b>						
By our Directors	Nil	Nil	N.A	N.A	Nil	Nil
Against our Directors	Nil	9 <sup>^</sup>	7 <sup>#</sup>	N.A	Nil	16.98
<b>Promoters</b>						
By our Promoters	Nil	Nil	N.A	N.A	Nil	Nil
Against our Promoters	Nil	9 <sup>^</sup>	6 <sup>#</sup>	Nil	Nil	16.98
<b>Key Managerial Personnel</b>						
By our Key Managerial Personnel	Nil	N.A	N.A	N.A	N.A	Nil
Against our Key Managerial Personnel	Nil	N.A	6 <sup>#</sup>	N.A	N.A	Nil
<b>Senior Management</b>						
By our Senior Management	Nil	N.A	N.A	N.A	N.A	Nil
Against our Senior Management	Nil	N.A	Nil	N.A	N.A	Nil

\* To the extent quantifiable.

<sup>^</sup> Includes the matters against Directors who are also Promoters.

<sup>#</sup> Includes the matters against the Company, which also involved the Directors, who are Promoters and KMPs of the Company as well.

Further, there are no outstanding litigation proceedings involving our Group Company, the adverse outcome of which may have a material impact on our Company.

For further details of the outstanding litigation proceedings, see “Outstanding Litigation and Material Developments” on page 378 of the RHP.

- B. Brief details of pending other material outstanding litigations against the Company and amount involved:

Sr. No.	Particulars	Litigation filed by	Current Status	Amount involved
1.	The Drugs Inspector, Central Drugs Standard Control Organisation, West Zone, Mumbai filed a complaint dated July 21, 2020 (“Complaint”), before the court of the Judicial Magistrate First Class, Ulhasnagar, Maharashtra (“District Court”), under Sections 18(a)(i), 16, 34 and 27(d) of the Drugs and Cosmetics Act, 1940, as amended, (“Drugs and Cosmetics Act”) against our Company, certain of our Directors, namely Viral Bhupendrabhai Sitwala, Ankur Kirtikumar Mehta and Dr. Kirtikumar Laxmidas Mehta and certain of our Shareholders, namely Brinda Mehta and Minaxi Mehta (together, the “Defendants”), alleging that certain products containing a drug COR-3 manufactured by us, are not of standard quality, in contravention of the Drugs and Cosmetics Act. The District Court, pursuant to its order dated February 28, 2022 (“Impugned Order”), issued the process against the Defendants, holding them responsible for the conduct of the business of the Company.	The Drugs Inspector, Central Drugs Standard Control Organisation, West Zone	The Defendants, including our Company filed a criminal application dated August 2, 2024, before the High Court of Judicature at Mumbai (“Mumbai High Court”) under Section 482 of the Code of Criminal procedure, 1973, praying for the quashing and setting aside of the Complaint as well as the Impugned Order. The matter is currently pending.	-
2.	Drugs Inspector, Central Drugs Standard Control Organisation, West Zone, Mumbai filed a complaint dated July 21, 2020 (“Complaint”), before the court of the Judicial Magistrate First Class, Ulhasnagar, Maharashtra (“District Court”), under Sections 18(a)(i), 16, 34 and 27(d) of the Drugs and Cosmetics Act, 1940, as amended, (“Drugs and Cosmetics Act”) against our Company, certain of our Directors, namely Viral Bhupendrabhai Sitwala, Ankur Kirtikumar Mehta and Dr. Kirtikumar Laxmidas Mehta and certain of our Shareholders, namely Brinda Mehta and Minaxi Mehta (together, the “Defendants”), alleging that certain products containing a drug B-29 manufactured by us, are not of standard quality, in contravention of the Drugs and Cosmetics Act. The District Court, pursuant to its order dated February 28, 2022 (“Impugned Order”), issued the process against the Defendants, holding them responsible for the conduct of the business of the Company.	The Drugs Inspector, Central Drugs Standard Control Organisation, West Zone	The Defendants, including our Company filed a criminal application dated August 2, 2024, before the High Court of Judicature at Mumbai (“Mumbai High Court”) under Section 482 of the Code of Criminal procedure, 1973, praying for the quashing and setting aside of the Complaint as well as the Impugned Order. The matter is currently pending.	-

**IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS**

3.	The Drugs Inspector, Solapur, Food and Drug Administration, Maharashtra filed a complaint dated August 27, 2012 before the Court of the Chief Judicial Magistrate, Solapur, Maharashtra, under Section 17(B)(d), 17(b), 18(a)(i), 18(a)(iv), 27(c) and 27(d) of the Drugs and Cosmetics Act, 1940, as amended, (“ <b>Drugs and Cosmetics Act</b> ”) and the rules thereunder, against our Company, our Director Viral Bhupendrabhai Sitwala and certain of our employees, alleging manufacture of certain drugs which were spurious in nature and misbranded, leading to a violation of the relevant provisions of the Drugs and Cosmetics Act.	Drugs Inspector, Solapur, Food and Drug Administration, Maharashtra	The matter is currently pending.	-
4.	The Drug Inspector, Jhansi, Food Safety and Drugs Administration, Uttar Pradesh, filed a complaint dated July 1, 2021 (“ <b>Complaint</b> ”) before the court of the Additional District and Sessions Judge, Jhansi, Uttar Pradesh, under Section 17A, 18(a)(i), 27(b)(i) and 27(d) of the Drugs and Cosmetics Act, 1940, as amended, (“ <b>Drugs and Cosmetics Act</b> ”) and the rules thereunder, against our Company, our Directors Ankur Kirtikumar Mehta, Dr. Kirtikumar Laxmidas Mehta and Viral Bhupendrabhai Sitwala, our Shareholders Vrinda Mehta and Minaxi Mehta, and certain others alleging manufacture and sale of low quality/ substandard drugs.	Drug Inspector, Jhansi, Food Safety and Drugs Administration, Uttar Pradesh	During the pendency of the matter, our Company filed an application dated November 20, 2021 under Section 482 of the Code of Criminal Procedure, 1973, before the High Court of Judicature at Allahabad, praying for the quashing of the proceedings arising from the Complaint and a summoning order dated July 22, 2021 passed by the Additional District and Sessions Judge, Jhansi, Uttar Pradesh. The High Court of Judicature at Allahabad has, by way of an order dated May 25, 2022, directed that no coercive action shall be taken against the Company until the next date of listing. The matter is currently pending.	-
5.	The State of Bihar through Drug Inspector, Muzaffarpur, Drugs Control Administration, filed a complaint dated January 11, 2022 (“ <b>Complaint</b> ”) before the court of the Special Judge Drugs and Cosmetics Act, Muzaffarpur, against our Company, certain of our Directors and the erstwhile company secretary of our Company, for violations of rules 74, 80 and 83 of the New Drugs and Clinical Trials Rules, 2019, as amended read with Section 18(a)(vi) and 18B of the Drugs and Cosmetics Act, 1940, as amended (“ <b>Drugs and Cosmetics Act</b> ”), alleging irrationality and non-compliance with applicable laws pertaining to the manufacture of GB-29 Total tablets by our Company and allegedly dealing in fixed-dose combination drugs without having the requisite permission from Drug Controller General. The Directors named in the Complaint and the erstwhile company secretary of our Company filed a criminal miscellaneous application dated August 31, 2023, before the High Court of Judicature at Patna (“ <b>Patna High Court</b> ”) for quashing the proceedings arising from the Complaint under section 482 of the Code of Criminal procedure, 1973.	Drug Inspector, Muzaffarpur, Drugs Control Administration	Pursuant to an order dated August 8, 2024, the Patna High Court stayed the proceedings arising from the Complaint till the pendency of the matter before the Patna High Court. The matter is currently pending.	-
6.	The Union of India, through Drug Inspector, Central Drugs Standard Control Organisation, Sub-Zone Jammu, filed a complaint dated July 26, 2018 (“ <b>Complaint</b> ”) before the court of the Chief Judicial Magistrate, Jammu, against our Company, certain of our Directors, namely Ankur Kirtikumar Mehta, Dr. Kirtikumar Laxmidas Mehta, Niravkumar Kirtikumar Mehta and Viral Bhupendrabhai Sitwala, our Shareholders Brinda Mehta and Meena Mehta, and certain others, under Sections 18(a)(i) and 27(d) of the Drugs and Cosmetics Act, 1940, as amended, (“ <b>Drugs and Cosmetics Act</b> ”) for allegedly manufacturing, selling and distributing Desogestrel & Ethinylestradiol (Locipil tablets) which were not of standard quality under section 18(a) read with section 16 punishable under section 27(d) of the Drugs and Cosmetics Act.	Drug Inspector, Central Drugs Standard Control Organisation, Sub-Zone Jammu	Ankur Kirtikumar Mehta, Dr. Kirtikumar Laxmidas Mehta, Niravkumar Kirtikumar Mehta filed a criminal miscellaneous petition dated May 1, 2019, before the High Court of Jammu and Kashmir for quashing the proceedings arising from the Complaint and an order dated July 26, 2018, passed by the Chief Judicial Magistrate, Jammu, issuing process and summons against them under section 561(A) of the Code of Criminal procedure, 1973. The matter is currently pending.	-

C. Disciplinary action taken by SEBI or stock exchanges against the Promoters in last 5 financial years including outstanding action, if any: Nil.

D. Brief details of outstanding criminal proceedings against the Promoters: Nil.

**ANY OTHER IMPORTANT INFORMATION AS PER BOOK RUNNING LEAD MANAGERS/COMPANY - NIL**

**DECLARATION BY OUR COMPANY**

We hereby certify and declare that all relevant provisions of the Companies Act, 2013 and the rules, regulations and guidelines issued by the Government of India, or the rules, regulations or guidelines issued by the Securities and Exchange Board of India, established under Section 3 of the Securities and Exchange Board of India Act, 1992, as the case may be, have been complied with, and no statement made in this Red Herring Prospectus is contrary to the provisions of the Companies Act, 2013, the Securities Contracts (Regulation) Act, 1956, the Securities Contract (Regulation) Rules, 1957 and the Securities and Exchange Board of India Act, 1992, each as amended, or the rules, regulations or guidelines issued thereunder, as the case may be. We further certify that all the disclosures and statements made in the Red Herring Prospectus are true and correct.

**DECLARATION BY THE SELLING SHAREHOLDERS**

Each of the Selling Shareholders, hereby confirm that all statements, disclosures and undertakings specifically made or confirmed by us in the Red Herring Prospectus in relation to ourselves, as a Selling Shareholder and our portion of the Offered Shares, are true and correct. We assume no responsibility for any other statements, disclosures and undertakings, including, any of the statements, disclosures and undertakings made or confirmed by or relating to the Company or any other Selling Shareholder(s) or any other person(s) in the Red Herring Prospectus.